Tags

Type your tag names separated by a space and hit enter

A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
Neurol Sci. 2020 May 10 [Online ahead of print]NS

Abstract

BACKGROUND

Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS).

OBJECTIVE

To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS).

METHODS

Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group.

RESULTS

Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM.

CONCLUSIONS

Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.

Authors+Show Affiliations

Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.MS Centre, Neurology Unit, Cardarelli Hospital, Naples, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.Multiple Sclerosis Center, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy. simona.bonavita@unicampania.it.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32388646

Citation

Lanzillo, R, et al. "A Snapshot On Patient-reported Outcome Measures of People With Multiple Sclerosis On First-line Therapies in a Real World Setting." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020.
Lanzillo R, Sparaco M, Lavorgna L, et al. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurol Sci. 2020.
Lanzillo, R., Sparaco, M., Lavorgna, L., Carmisciano, L., Signoriello, E., Signori, A., Costabile, T., Maniscalco, G. T., Saccà, F., Cepparulo, S., Russo, C. V., Bisecco, A., Frattaruolo, N., Strianese, A., Lus, G., Brescia Morra, V., & Bonavita, S. (2020). A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://doi.org/10.1007/s10072-020-04367-9
Lanzillo R, et al. A Snapshot On Patient-reported Outcome Measures of People With Multiple Sclerosis On First-line Therapies in a Real World Setting. Neurol Sci. 2020 May 10; PubMed PMID: 32388646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. AU - Lanzillo,R, AU - Sparaco,M, AU - Lavorgna,L, AU - Carmisciano,L, AU - Signoriello,E, AU - Signori,A, AU - Costabile,T, AU - Maniscalco,G T, AU - Saccà,F, AU - Cepparulo,S, AU - Russo,C V, AU - Bisecco,A, AU - Frattaruolo,N, AU - Strianese,A, AU - Lus,G, AU - Brescia Morra,V, AU - Bonavita,S, Y1 - 2020/05/10/ PY - 2019/12/28/received PY - 2020/03/20/accepted PY - 2020/5/11/entrez PY - 2020/5/11/pubmed PY - 2020/5/11/medline KW - Disease-modifying therapies KW - First-line therapies KW - Multiple sclerosis KW - Patient-reported outcomes JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol. Sci. N2 - BACKGROUND: Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). OBJECTIVE: To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS). METHODS: Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group. RESULTS: Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM. CONCLUSIONS: Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/32388646/A_snapshot_on_patient-reported_outcome_measures_of_people_with_multiple_sclerosis_on_first-line_therapies_in_a_real_world_setting L2 - https://link.springer.com/10.1007/s10072-020-04367-9 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.